Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ACP3 | P15309 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190054 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2SIGMAR1CHRM2L3MBTL1ATM | |
| SCHEMBL9063682 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2SIGMAR1CHRM2L3MBTL1ATM | |
| Hydrochloric Acid SCHEMBL3756451 | 0.98 | SMN1; SMN2 (0.59) | SMN1; SMN2SIGMAR1CHRM2L3MBTL1ATM | |
| SCHEMBL11883479 | 0.96 | SMN1; SMN2 (0.56) | SMN1; SMN2SIGMAR1CHRM2L3MBTL1ATM | |
| SCHEMBL11884253 | 0.91 | CASR (0.53) | SMN1; SMN2SIGMAR1CHRM2L3MBTL1ATM | |
| SCHEMBL8092732 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2SIGMAR1CHRM2L3MBTL1ATM | |
| SCHEMBL7176511 | 0.88 | MEN1 (0.49) | SMN1; SMN2CHRM2L3MBTL1MEN1KMT2A | |
| SCHEMBL8091287 | 0.88 | L3MBTL1 (0.57) | SMN1; SMN2CHRM2L3MBTL1ATMMEN1 | |
| SCHEMBL8092329 | 0.85 | TDP1 (0.59) | SMN1; SMN2L3MBTL1MEN1KMT2ACASR | |
| SCHEMBL27826995 | 0.85 | TDP1 (0.56) | SMN1; SMN2CHRM2L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275779-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | KANEKA CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1942103-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | Kaneka Corporation (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275779-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | SMS, SRM, ABHD5 | SMN1; SMN2 2659/4885SIGMAR1 1340/4885CHRM2 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.